# Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

> **NCT01376713** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 10 (actual)

## Conditions studied

- Stage III Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** Ofatumumab
- **BIOLOGICAL:** Ofatumumab plus Dacarbazine

## Key facts

- **NCT ID:** NCT01376713
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-01
- **Final completion:** 2015-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376713, "Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01376713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*